Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding Ltd
(OP:
RHHVF
)
336.07
+1.64 (+0.49%)
Streaming Delayed Price
Updated: 2:46 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Roche Holding Ltd
< Previous
1
2
3
4
5
6
7
Next >
No More Free COVID-19 At-Home Tests, Federal Government Says
August 29, 2022
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au
Via
Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).
Via
Benzinga
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech
August 18, 2022
Via
Benzinga
Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
August 16, 2022
Via
Benzinga
FDA Approves Expanded Use Of Roche's Influenza Treatment
August 12, 2022
Via
Benzinga
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
August 08, 2022
Via
Benzinga
Poseida Shares Rally As Roche Takes Next Big Step Into Allogeneic CAR-T Field
August 03, 2022
Via
Benzinga
Regeneron's Price Target Cut On Dim Prospects For Its Flagship Eye Product
July 25, 2022
Via
Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
July 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Roche's Long-Time CEO Passes Baton, Higher Diagnostics, Medicine Sales Lift 1H Sales & Profit
July 21, 2022
Via
Benzinga
Roche Launches Dual Antigen & Antibody Hepatitis C Diagnostic Test
July 18, 2022
Via
Benzinga
New Data Reinforce Favorable Safety, Efficacy Of Roche's Hemlibra For Hemophilia A
July 11, 2022
Via
Benzinga
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial
July 06, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Roche-AC Immune's Crenezumab Fails To Show Benefit In Sub-Set Of Alzheimer's Patients
June 16, 2022
Via
Benzinga
Early Data Shows BioNTech's Personalized Therapy Safe In Pancreatic Cancer Patients
June 06, 2022
Via
Benzinga
Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer
May 23, 2022
Via
Benzinga
Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer
May 11, 2022
Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung...
Via
Benzinga
Roche Releases More Evrysdi Data For Very Young Infants With SMA
April 29, 2022
Via
Benzinga
Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials
April 25, 2022
The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.
Via
Benzinga
COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook
April 25, 2022
Via
Benzinga
EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs
April 22, 2022
Via
Benzinga
FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis
April 20, 2022
The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...
Via
Benzinga
Read Why Pliant Therapeutics Shares Are Soaring Today
April 13, 2022
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.
Via
Benzinga
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis
April 04, 2022
Via
Benzinga
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults
April 04, 2022
Via
Benzinga
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial
March 30, 2022
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)
Via
Benzinga
Drug makers, Scientists Working For Long COVID Treatments: Reuters
March 25, 2022
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,
Via
Benzinga
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population
March 16, 2022
Via
Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
March 15, 2022
Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.